CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer. Ms. Huntsman was most recently Senior Vice President, Head of Specialty Care North America and U.S.…Read More
Related Posts
Rates of septic revision after TKA declined from 2010 to 2019
GRAPEVINE, Texas -- Results presented here showed overall unadjusted rates of septic revisions after total knee arthroplasty declined from 2010 to 2019, with this trend remaining after adjusting for various…
Guest opinion Utah can get healthier with printed patient medication information
Utah takes pride in health. In 2023, Utah ranked second in the nation in the health of our population. Utah is also the happiest state in the country, flowing from…
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis RA Clinical…
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. XBIT today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as…
